SCHEMBL231793

SCHEMBL231793

C[CH]c1cccc2c1CCC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.45
BAD Q92934 1/20 0.45
ALDH1A1 P00352 5/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
NISCH Q9Y2I1 1/20 0.37
TSHR P16473 1/20 0.37
LMNA P02545 2/20 0.35
SIGMAR1 Q99720 1/20 0.35
MEN1 O00255 1/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
KMT2A Q03164 1/20 0.35
RXRA P19793 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30777455 0.79 BCL2L1 (0.45) BCL2L1BADALDH1A1MAPTSMN1; SMN2
SCHEMBL1616679 0.79 BCL2L1 (0.45) BCL2L1BADALDH1A1MAPTSMN1; SMN2
SCHEMBL9136887 0.75 BCL2L1 (0.50) BCL2L1BADALDH1A1SMN1; SMN2TSHR
SCHEMBL1044992 0.75 BCL2L1 (0.50) BCL2L1BADALDH1A1SMN1; SMN2TSHR
SCHEMBL19249411 0.73 BCL2L1 (0.48) BCL2L1BADALDH1A1SMN1; SMN2TSHR
Dimethylamine SCHEMBL6542151 0.73 BCL2L1 (0.44) BCL2L1BADALDH1A1TSHRLMNA
SCHEMBL413550 0.73 BCL2L1 (0.52) BCL2L1BADALDH1A1MAPTSMN1; SMN2
SCHEMBL29892288 0.73 BCL2L1 (0.52) BCL2L1BADALDH1A1MAPTSMN1; SMN2
SCHEMBL31462459 0.72 BCL2L1 (0.33) BCL2L1BADNPSR1
SCHEMBL10651162 0.72 BCL2L1 (0.47) BCL2L1BADALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239805-A1 AZA-YANG CYCLIZATION-BUCHNER AROMATIC RING EXPANSION: COLLECTIVE SYNTHESIS OF CYCLOHEPTATRIENE-CONTAINING AZETIDINE LACTONES UNIVERSITY OF KANSAS 2024-07-18 US disclosed
EP-4398911-A2 INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS Memorial Sloan Kettering Cancer Center (US) 2024-07-17 EP disclosed
US-12037414-B2 Processes for preparing pharmaceutically relevant peptides STEALTH BIOTHERAPEUTICS INC. (US) 2024-07-16 US disclosed
US-12024515-B2 Kifunensine derivatives UNIVERSITY OF KANSAS (US) 2024-07-02 US disclosed
EP-4384524-A1 DERIVATIVES OF TURBINMICIN AS ANTIFUNGAL AGENTS Wisconsin Alumni Research Foundation (US) 2024-06-19 EP disclosed
WO-2024123818-A1 FUNCTIONALIZED COLLOIDAL SILICA AND METHODS OF PRODUCTION W.R. GRACE & CO.-CONN (US) 2024-06-13 WO disclosed
EP-4370701-A1 TEXTILES DERIVED FROM FOOD WASTE AND PROCESSES OF MAKING THEREOF Alt Tex Inc. (CA) 2024-05-22 EP disclosed
WO-2024102441-A1 PROCESSING AID FORMULATION AND POLYOLEFIN FILMS MADE THEREFROM Amcor Flexibles North America, Inc. (US) 2024-05-16 WO disclosed
WO-2024097229-A1 PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED DERMATOLOGICAL CONDITIONS BACAINN BIOTHERAPEUTICS, INC. (US) 2024-05-10 WO disclosed
WO-2024097945-A1 PRODRUGS FOR MITOCHONDRIAL CALCIUM UPTAKE INHIBITORS CORNELL UNIVERSITY (US) 2024-05-10 WO disclosed
US-20110009628-A1 Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same CVI PHARMACEUTICALS LIMITED (KY) 2011-01-13 US disclosed
WO-2011006000-A1 BERBERINE DERIVATIVES USEFUL FOR MODULATING LIPID LEVELS AND THEIR METHODS OF SYNTHESIS LIU HAIYAN (US) 2011-01-13 WO disclosed
WO-2010143062-A1 COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORONARY HEART DISEASES GENEREX PHARMACEUTICALS, INC. (CN) 2010-12-16 WO disclosed
US-20100261871-A1 CONFORMATIONALLY CONSTRAINED PEPTIDE MIMETICS INDIAN INSTITUTE OF SCIENCE 2010-10-14 US disclosed
US-20100228004-A1 TEMPLATES FOR NUCLEATION AND PROPAGATION OF PEPTIDE SECONDARY STRUCTURE EMPIRE TECHNOLOGY DEVELOPMENT LLC 2010-09-09 US disclosed
US-20100048637-A1 CYCLOHEXYLAMINES, PHENYLAMINES AND USES THEREOF PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) 2010-02-25 US disclosed
WO-2010014948-A1 METHODS OF TREATMENT USING WNT INHIBITORS THE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2010-02-04 WO disclosed
US-20100016638-A1 Method for preparation of o-desmethylvenlafaxine using polythiolates PLIVA HRVATSKA D.O.O (HR) 2010-01-21 US disclosed
US-20090048246-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2009-02-19 US disclosed
WO-2009002873-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS CVI PHARMACEUTICALS LIMITED (KY) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239805-A1 AZA-YANG CYCLIZATION-BUCHNER AROMATIC RING EXPANSION: COLLECTIVE SYNTHESIS OF CYCLOHEPTATRIENE-CONTAINING AZETIDINE LACTONES AZI2, NISCH, TET2 BCL2L1 2299/4885BAD 230/4885ALDH1A1 1283/4885
US-20110009628-A1 Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same LIPC, LDLR, PCSK9 BCL2L1 1983/4885BAD 2706/4885ALDH1A1 3512/4885
US-20100016638-A1 Method for preparation of o-desmethylvenlafaxine using polythiolates CYP4F3, CYP2F1, CYP4F2 BCL2L1 4024/4885BAD 4166/4885ALDH1A1 1755/4885
US-20100228004-A1 TEMPLATES FOR NUCLEATION AND PROPAGATION OF PEPTIDE SECONDARY STRUCTURE IAPP, NGLY1, HDGF BCL2L1 2537/4885BAD 3601/4885ALDH1A1 4099/4885
US-20100048637-A1 CYCLOHEXYLAMINES, PHENYLAMINES AND USES THEREOF SMO, HNMT, INMT BCL2L1 2596/4885BAD 1131/4885ALDH1A1 915/4885
US-12037414-B2 Processes for preparing pharmaceutically relevant peptides ADM2, VIP, PEPD BCL2L1 4695/4885BAD 4212/4885ALDH1A1 4638/4885
US-20100261871-A1 CONFORMATIONALLY CONSTRAINED PEPTIDE MIMETICS IAPP, VIP, HM13 BCL2L1 1037/4885BAD 611/4885ALDH1A1 4832/4885
US-20090048246-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS LIPC, BCHE, LIPE BCL2L1 3358/4885BAD 1189/4885ALDH1A1 4483/4885
US-12024515-B2 Kifunensine derivatives MAN2B1, MAN2A1, MANBA BCL2L1 3080/4885BAD 3228/4885ALDH1A1 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.